Abstract | INTRODUCTION: AIMS: To update the evidence and provide an overview of the available data on ticagrelor. EVIDENCE REVIEW: PLACE IN THERAPY: CONCLUSION: The options for drugs to inhibit the platelet P2Y12 receptor for adenosine diphosphate are rapidly expanding. Ticagrelor has shown benefits in clinical trials. Its rapid onset of platelet inhibition and short half-life make it an attractive alternative to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.
|
Authors | Bernardo Lombo, José G Díez |
Journal | Core evidence
(Core Evid)
Vol. 6
Pg. 31-42
( 2011)
ISSN: 1555-175X [Electronic] New Zealand |
PMID | 21468241
(Publication Type: Journal Article)
|